Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells

  • End date
    Dec 1, 2024
  • participants needed
  • sponsor
    University of Kansas Medical Center
Updated on 9 December 2021
inclusion body myositis


This is an open-label, single arm study evaluating the safety for patients with Inclusion Body Myositis. A total of 9 subjects will be enrolled in the study. Subjects will be randomized to Part 1 or Part 2 of the study in blocks of 3 every 3 months. Stem cell injections will be given in the forearm and thigh on either the left or right side of the body, depending on which side meets criteria. The overall goal of this pilot study is to test the safety of adipose derived regenerative cells in patients with Inclusion Body Myositis. If determined safe, this trial could lead to larger Phase II trials. While this specific trial's primary endpoint is safety, it our ultimate hope that ADRC injections into the forearm and thigh of IBM patients will slow, stabilize, or even reverse the progression of muscle weakness in patients with IBM.


Inclusion Body Myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over age 50 years, with an annual incidence estimated at 2.2 to 7.9 per million. IBM causes both proximal and distal muscle weakness, characteristically most prominent in the quadriceps and finger flexors. Over time it can lead to severe disability, including loss of hand function, falls due to quadriceps muscle weakness and foot drop, dysphagia, and eventually respiratory muscle weakness. There is no effective therapy for IBM.

This study, "Inclusion Body Myositis Treatment with Celution Processed Adipose Derived Regenerative Cells" (IBM-ADRC) evaluates the safety and efficacy of the Celution System in the processing of an autologous graft consisting of adipose-derived regenerative cells (ADRCs) in the treatment of inclusion body myositis. Specifically, the overall objective is for the proposed clinical trial to serve as a safety trial for Inclusion Body Myositis.

This is an open-label, single arm study evaluating the safety for patients with Inclusion Body Myositis. A total of 9 subjects will be enrolled in the study. Subjects will be randomized to Part 1 or Part 2 of the study in blocks of 3 every 3 months.

Enrollment is anticipated to be staggered into 3 groups. The nine subjects will be randomized 2:1 in groups of 3 to early injections (Part 2) versus late (Part 1).

Stem cell injections will occur unilaterally in the flexor digitorum profundus muscles and the quadriceps group of muscles.

Condition Idiopathic Inflammatory Myopathies, INCLUSION BODY MYOSITIS, Myositis
Treatment Adipose Derived Regenerative Cells
Clinical Study IdentifierNCT04975841
SponsorUniversity of Kansas Medical Center
Last Modified on9 December 2021


Yes No Not Sure

Inclusion Criteria

Meet any of the European Neuromuscular Centre Inclusion Body Myositis research diagnostic criteria 2011 categories for IBM. (see Appendix 3)
Demonstrate being able to arise from a chair without support from another person or device. Subjects may use their arms to push up
Able to ambulate at least 20 ft/6 meters with or without assistive device. Once arisen from the chair, participant may use any walking device, i.e. walker/frame, cane, crutches, or braces. They cannot be supported by another person and cannot use furniture or wall for support
Age at onset of weakness > 45 years
Able to give informed consent
Muscle strength graded between 6 and 9 for finger flexion and knee extension unilaterally on one side of the body (right or left) using the Kandell 0-10 scale. A subject may meet this criterion bilaterally and still be included in the study

Exclusion Criteria

History of any of the following excludes subject participation in the study: chronic infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer less than five years prior, or other chronic serious medical illnesses
Presence of any of the following on routine blood screening: WBC < 3000; platelets < 100,000; hematocrit < 30%; BUN > 30 mg/dL; creatinine > 1.5 x upper limit of normal; symptomatic liver disease with serum albumin < 3 g/dl
History of most recent creatine kinase >15x the upper limit of normal without any other explanation besides IBM
History of non-compliance with other therapies
Use of testosterone except for physiologic replacement doses in case of androgen deficiency. Participants must have documented proof of the androgen deficiency
Coexistence of any other neurological, cardiac, pulmonary, psychiatric, or rheumatologic disease that would likely to affect outcome measures
Drug or alcohol abuse within past three months. Patient has recent history (within 6 months before Screening) of chronic alcohol or drug abuse which may compromise the patient's safety or ability to participate in study activities
Use of cannabis
Participation in a recent drug study in the last 30 days prior to the screening visit or use of biologic agents less than 6 months prior to the screening visit
Women who are lactating or pregnant, or men or women unwilling to use a highly effective method of birth control if not surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy for women; vasectomy for men) for both male and female participants until 4 weeks after last dose. Pre-menopausal women must have a negative pregnancy test prior to dosing with trial medication. Acceptable methods of birth control are
Hormonal methods associated with inhibition of ovulation such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before IMP administration
ii. Total abstinence from sexual intercourse since the last menses before IMP
administration. (The reliability of sexual abstinence needs to be evaluated in
relation to the duration of the clinical trial and the preferred and usual
lifestyle of the subject. Periodic abstinence (calendar, symptothermal, post-
ovulation methods), are not acceptable methods of contraception)
iii. Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
If the subject is a sexually active male with female partners of child-bearing
potential (postmenarchal) he must use a condom with or without spermicide in
addition to the birth control used by his partners during the trial until 3
months after the last dose of trial medication. Non child-bearing potential
is defined as post-menopausal (minimum of 12 months with no menses and
follicle-stimulating hormone in the post-menopausal range) or sterilisation
(hysterectomy, oophorectomy, or bilateral tubal ligation)
\. Participants taking corticosteroids within the previous 30 days prior to
screening. Participants on intravenous immunoglobulin (IVIg) or other
immunosuppressants within the last 3 months. Topical, nasal, and ocular
corticosteroids are allowed unless they are being widely applied or the
severity of the underlying condition makes them unsuitable in the
Investigator's opinion. Local steroid injections are allowed
\. Patients who have aPTT (Activated Partial Thromboplastin Time) values 1.8
X the normal value
\. Patients who have received any anticoagulant within 1 hour prior to
\. Patients who have received any anticoagulant within 1 hour of stem cell
\. Patients who are on substantial anticoagulation (eg: GIIb/IIIa inhibitor
class drugs) who cannot stop it within two weeks prior to adipose harvest
\. Participants who's IBM age of onset is under of 45
\. Participants with an elevated alkaline phosphatase level which may
indicate Paget disease
\. Participants allergic or sensitive to lidocaine and or epinephrine
\. Participants with known drug exposures associated with neuromuscular side
effects including antimalarial drugs (eg, chloroquine, hydroxychloroquine)
colchicine, glucocorticoids, cholesterol-lowering drugs (eg, HMG-CoA reductase
inhibitors [statins]) except if on stable dose for more than a year without
impact on IBM progression, alcohol abuse, and cocaine
\. Use of other concomitant myositis treatment drugs, or cell or gene
therapies (e.g. Arimoclomol, Bimagrumab, Follistatin, Rapamycin)
\. Any patient with an area of active skin infection at the site of
\. Participants that are current smokers, defined as an adult who has smoked
cigarettes in his or her lifetime and who currently smokes cigarettes
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note